Clinical Trial News Archive
Get news by email or subscribe to our news feeds.
News Archive for September 2007
September 4, 2007
- Study Shows Combination Therapy Incorporating Avodart and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
- Clinical Data Announces Positive Results from Phase III Pivotal Trial of Vilazodone for Depression
- NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
- Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
- Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher Sirolimus-Eluting Coronary Stent and Taxus Stent
- New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
- SPP100 (Tekturna/Rasilez) Promising Results in Patients with Heart Failure
- Angiox (Bivalirudin) Alone Reduced Early Bleeding and Resulted in Similar One-Year Mortality Compared to Heparins Plus GP IIb/IIIa Combination Therapy in ACS Patients Undergoing Angioplasty
- Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER Sirolimus-eluting Coronary Stent Compared to Taxus Stent
- Study Published in Clinical Cancer Research Confirms Potential Of Peregrine's Bavituximab Combined With Radiation In Lung Cancer
- Data from Patient Subsets of e-HEALING, a Worldwide Registry, Support Use of OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) as Alternative to Drug- Eluting Stents
- Cypher Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
- Cell That Triggers Symptoms in Allergy Attacks Can Also Limit Damage, Stanford Researchers Find
- Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
- New Study Findings Confirm Clexane/Lovenox Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
- Metabasis Therapeutics Announces Publication of Its Novel Computer-Aided Drug Design Technology for Drug Discovery in the Journal of the American Chemical Society
- Safety Profile of Taxus Liberte Stent System Highlighted in World's Largest Stent Registry
- Over 80% of Patients on ATC Achieve Undetectable HIV After 24 Weeks
- Pharmexa Presents Data from Malaria Vaccine on International Vaccine Conference
- PhytoMedical Releases Preliminary Research Results For New Class of Diabetes Compounds
- Major ADVANCE for Type 2 Diabetics
- New Study Demonstrates Patients Who Were Informed of Their Risk of Cardiovascular Disease Lowered Their Predicted Risk for Coronary Heart Disease
- Study Shows Rasilez, the First and Only Approved Direct Renin Inhibitor, Reduces a Marker of Heart Failure Severity and is Well-Tolerated
- First PAH Functional Class II Population Study Emphasizes Need to Diagnose and Treat PAH Early
- New Data On Orexin Receptor Antagonist Almorexant Shows Therapeutic Potential to Restore Normal Physiological Sleep in Patients Suffering From Insomnia
- Roche's Tarceva Delivers Longer Life for Lung Cancer Patients
- Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
- American Heart Association Comment Saving Lives in Type 2 Diabetics: Could It Be as Easy as Lowering Blood Pressure?
- Next Pharmaceuticals Announces Results of Relora Open Label Study
September 5, 2007
- Depomed Announces Positive Results of Phase 2a Proof-of-Concept GERD Study
- Pharmacyclics Announces Encouraging Phase 2 Data With Xcytrin in Recurrent Non-Small Cell Lung Cancer Patients
- Salix Announces Statistically Significant Top-Line Results of a Unique Granulated Mesalamine Product Registration Study in Ulcerative Colitis
- Rifaximin Demonstrates Statistically Significant Improvement in Co-Primary Endpoints in Treatment of Diarrhea-Associated Irritable Bowel Syndrome in Phase IIb Study
- Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie
- Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Study Shows Iressa (Gefitinib) Is As Effective As Docetaxel In Pre-Treated Advanced NSCLC
- AKELA Pharma Inc. Announces Positive Results for The Extension Part of its Phase IIb Fentanyl Taifun Trial
- REACH Registry Highlights That Patients With Peripheral Arterial Disease (PAD) Suffer High Rates of Heart Attack, Stroke, Hospitalization, and Death
- Taxus Woman Study Reports Positive Clinical Outcomes for the Taxus Drug-eluting Stent in Women
- Stimuvax Phase II Data Highlight Three-Year Survival Results for Patients with Non-Small Cell Lung Cancer
- Genasense Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
- Patients Who Switched from Established Lipitor Therapy to Simvastatin Experienced a Significant 30 Percent Increase in Relative Risk of Cardiovascular Events or Death, New Observational Study Shows
- Pieris Validates the Use of Anticalins as Ophthalmologic Biotherapeutics
- Four Analyses of Three-Year Clinical Data Suggest CYPHER Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
- Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
- Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa
- Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
- International Stem Cell Corporation Creates Human Cornea Tissue from Its Parthenote Stem Cells; Preliminary Discovery Holds Promise to Aid in Therapy for Blindness
- Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
- Access and Somanta Announce New Data on Angiolix Humanized Monoclonal Antibody
- Stimuvax Therapeutic Cancer Vaccine – Phase II Data Highlight Three-Year Survival Results for Lung Cancer Patients
- Positive Survival Data from ASA404 Trial Presented at World Conference on Lung Cancer
- Genasense Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
- DOR BioPharma Announces Publication Describing Protection Against Oral and Aerosol Ricin Exposure With Its Ricin Vaccine RiVax
- One of the Largest Post-WHI Physician Surveys Shows More Education is Needed: Patient Misinformation About Hormone Therapy Remains High
- New Data Show Olmesartan, an Angiotensin Receptor Blocker (ARB) Has Significant Anti-Atherosclerotic and Vascular Protective Effects
September 6, 2007
- XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
- Results from Study Evaluating Procrit in Intensive Care Unit Patients Published in New England Journal of Medicine
- The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
- Idera Pharmaceuticals Presents Interim Data from Phase 1 Study Evaluating IMO-2055 in Combination with Gemcitabine and Carboplatin
- Link Uncovered Between Benign Prostatic Hyperplasia and NSAIDs, Says Harvard Men's Health Watch
- Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
- Boehringer Ingelheim to Initiate First Phase III Pivotal Study for New Oncology Compound BIBW 2992
- New Flu Vaccine from PepTcell Could Provide Immunity Against All Strains of Influenza Virus - Sep 6, 2007
- Aranesp Study Showing No Negative Impact on Survival in SCLC Presented at World Conference on Lung Cancer
- Study Identifies Genetic Risk Factor for Rheumatoid Arthritis, Lupus
- Nymox BPH Drug Data Presentation September 8 at American Urological Association Meeting
- OSI Pharmaceuticals Announces Positive Results from a Metformin Drug Interaction Study with Its DP-IV Inhibitor, PSN9301
September 7, 2007
- Arius Features Preclinical Data on Antibody Candidates at Two Conferences
- Genmab Announces Encouraging Preclinical Data for Ofatumumab
- OSI Pharmaceuticals Summarizes Data Presented on Tarceva (erlotinib) at the 12th World Congress on Lung Cancer Meeting
- Pharmexa Presents New Data from Two Experimental Flu Vaccines on International Vaccine Conference
- Pharmaceuticals Holding AG Publication in LANCET Neurology Highlights Potential of Santhera's SNT-MC17 for Friedreich's Ataxia
- Protox To Present Interim Prostate Cancer Data at AUA Conference
- Zemiva Normals Database From Molecular Insight Pharmaceuticals, Inc. Enables Accurate Determination of Abnormal Heart Activity
- Global Survey Reveals Significant Gap in Meeting World's Mental Health Care Needs
- Innogenetics Reports Top-line Results of Second Placebo-controlled Clinical Trial with Candidate Hepatitis C Therapeutic E1 Vaccine
- Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
- Peregrine Reports Data Showing Bavituximab's Potential to Shrink Prostate Tumors
- Study Finds Heart Failure Is Rare Among Leukemia Patients on Imatinib
September 10, 2007
- Regeneron Announces Positive Results in Exploratory Proof-of-Concept Study of Rilonacept in Chronic Active Gout
- Outcomes Data Demonstrating Prognostic Value of Cytogen's PROSTASCINT Published in Peer-Reviewed Journal Urology
- R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
- Lev Pharmaceuticals Meets Primary Endpoint in Pivotal Phase III Prophylactic Trial for Hereditary Angioedema
- EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
- Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
- New Global Alliance Unveils Integrated Strategy to Combat Neglected Diseases in The New England Journal of Medicine
- XenoPort Announces Results of a Phase 1 Clinical Trial and Plans for Additional Phase 2 Clinical Trials of XP19986
- TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
- Data in the SinuNase Phase 3 Clinical Trial Predicts That Virtually 100% of Chronic Sinusitis Cases Are Due to a Fungal-Induced Inflammation
- MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
- Aspreva Provides Update On Lupus Nephritis Development Program
- Chelsea Therapeutics Resolves Bioavailability Issue and Reports Greater Than 10-Fold Improvement in Relative Bioavailability of New CH-1504 Formulation
- ValiRx - GeneICE & Cancer Research Technology Update
- Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
- Cleveland Clinic-Led Research Uncovers New Mechanism That Heightens Risk of Heart Disease
September 11, 2007
- Lev Pharmaceuticals, Inc. Phase III Clinical Update Conference Call
- NicOx Reports Topigen to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
- Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
- Amgen to Review Benefits, Risks of ESA Therapy in Chronic Renal Failure Patients at FDA Advisory Committee
- Reminder: XTL to Hold a Conference Call Today at 8:30 am EDT to Discuss the Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
- Erbitux Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
- S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies
- Erbitux Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
- Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
- Biothera's Imprime PGG Increases Efficacy of Erbitux against Non-Small Cell Lung Cancer, Study Finds
- Molecular Insight Pharmaceuticals, Inc. to Host Conference Call to Review Positive Zemiva Phase 2b Data Presented at ASNC
- Study Suggests Drug Used for Treatment for Heart Failure in Adults May Not Be Beneficial for Children and Teens
- Long-term Use of Glycemic Control Medication Rosiglitazone Associated with Increased Risk of Heart Attack and Heart Failure
- Glycemic Control Medication Pioglitazone Appears to Have Overall Favorable Effect Regarding Risk of Cardiovascular Events
- Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
September 12, 2007
- Hollis-Eden Pharmaceuticals Reports on Anti-Inflammatory Activity with HE3286 in Models of Diseases of Inflammation
- Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
- Reovirus Infection of Melanoma Cells Generates Anti-Tumour Immunity
- Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
- Advitech Announces New Efficacy Results for Dermylex and Compliance with FDA Regulations on Claims
- Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting
- Statistically Significant Efficacy of Juvista Demonstrated in Phase 2 Trial Using Drug Substance Manufactured by Lonza Biologics
- AVI BioPharma Drug Demonstrates Strong Survival Benefits and Elimination of Ebola Virus in Animals
- Customized Virus Kills Brain Tumor Stem Cells that Drive Lethal Cancer
- GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
- Cognitive Activities Protect Against Alzheimer's -- Social and Physical Activities Not Enough
- Manic Phase of Bipolar Disorder Benefits from Breast Cancer Medication
- New Topical Therapy Safely Treats Serious Skin Infections Without Systemic Side Effects
September 13, 2007
- BiDil Data to be Presented at Heart Failure Society of America Science Meeting
- Raptor Pharmaceuticals Provides Update of Product Programs
- Optimer to Present Data on Lead Antibiotic Candidates at ICAAC
- Vernalis Announces Striking Weight Loss in Phase I Study with V24343 in Overweight and Mildly Obese Volunteers
- Genasense Clinical Data in Patients with Advanced Melanoma and Chronic Lymphocytic Leukemia to be Presented at ECCO Meeting in Barcelona
- Critical Therapeutics Announces Publication of Results from Two Asthma Studies
- Xanthus' Xanafide is Unaffected by Multi-Drug Resistance in In Vitro Preclinical Studies in Leukemia Cells
- Basilea Pharmaceutica Ltd. (CH) - New Data to be Presented on Key Basilea Compounds at the Interscience Conference on Antimicrobial Agents and Chemotherapy
- Genmab Provides Insights into IgG4 Antibodies
September 14, 2007
- Largest Study To Date Finds Drug-Eluting Stents And Bare-Metal Stents Yield Similarly Low Mortality Rates
- Crucell N.V. (NL) - Crucell to present pre-clinical results for H5N1 Virus treatment
- Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
- The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
- Basilea Announces Positive Top-line Data from Phase III Study of Ceftobiprole in Community-acquired Pneumonia Requiring Hospitalization
September 17, 2007
- New Data for Galvus Provide Further Evidence of Robust Efficacy and Tolerability in Treating Patients with Type 2 Diabetes
- Immutep Announces That ImmuFact IMP321 Induces Activation of a Wide Range of Human Effector Cytotoxic Cells
- Trius Presents Study Results of Best-In-Class Antbiotics at ICAAC
- Sygnis’ AX200 shows efficacy in stroke patients – Phase IIa results exceed expectations
- New Data for Galvus Provide Further Evidence of Robust Efficacy and Tolerability in Treating Patients with Type 2 Diabetes
- Ligand Announces Positive Preclinical Data on Selective Androgen Receptor Modulator LGD-3303
- Cholesterol Byproduct Blocks Heart-health Benefits of Estrogen
- Polydex Pharmaceuticals Limited announces BV Trial results
- Oculus Innovative Sciences Microcyn Technology Data to be Presented by Researchers at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Pervasis Therapeutics Announces New Animal Study Results Supporting Vascugel in Promoting Healing After Blood Vessel Injury
- Risedronate Reduced Risk of Fracture Among Osteoporotic Postmenopausal Women with History of Hip Fracture
- Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
- Updated Revlimid Clinical Results Presented at the 12th International Workshop on Chronic Lymphocytic Leukemia
- Nanoviricides Go Beyond Antibodies in Fighting Bird Flu
- Basilea Presents Research Data at ICAAC on Novel Antibiotic Addressing the Emerging Threat from Multi-resistant Gram-negative Bacteria
- Scientific Results Presented at ICAAC Demonstrate the Well-differentiated Profile and Broad Spectrum of BioAlliance Pharma's Antifungal
- Idera Pharmaceuticals Presents Preclinical Data on IMO-2125 and Other TLR9 Agonists
- Study Presented on Use of Cancidas (caspofungin acetate) as Empirical Therapy of Suspected Invasive Fungal Infections in Pediatric Patients with Persistent Fever and Neutropenia
September 18, 2007
- First Osteoporosis Study in Patients with Hip Fracture Finds Once-Yearly Aclasta-Reclast Prevents Additional Fractures and Improves Survival
- New Data Support Long-Term Efficacy and Safety in Patients Who Took Exubera for Eight Years
- First Osteoporosis Study in Patients with Hip Fracture Finds Once-yearly Aclasta-reclast Prevents Additional Fractures and Improves Survival
- Aclidinium bromide demonstrates rapid and long-acting bronchodilatory effect in COPD
- Metabasis Therapeutics Presents Promising Preclinical Results with Its Novel Glucagon Antagonist for the Treatment of Type 2 Diabetes
- Study Presented on Use of Cancidas (caspofungin acetate) as Empirical Therapy of Suspected Invasive Fungal Infections in Pediatric Patients with Persistent Fever and Neutropenia
- Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of Velcade (Bortezomib) for Injection Based Therapy Across All Endpoints
- Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
- Sosei Announces Completion of Phase II Trial of AD 337 in Fibromyalgia Syndrome
- Ardea Presents Early-Stage HIV Data at ICAAC
- New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA/ritonavir vs. KALETRA as Part of HIV Combination Therapy
- New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
- Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
- Data Presented at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Demonstrate That INCB9471 is a Potent, Selective Inhibitor of the HIV-1 Virus with Excellent Pharmacokinetics Suitable for Once-Daily Dosing
- Isentress (raltegravir), in Combination with Optimized Background Therapy (OBT), Provided Sustained Viral Suppression in Highly Treatment-Experienced Patients Infected with HIV, through 48 Weeks
- Provectus Pharmaceuticals, Inc. Releases Summary Results of Phase 1 Metastatic Melanoma Study
- Sanofi Pasteur's Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
- Long-Term Data Reinforce Safety and Efficacy Profile of Pfizer's New HIV Drug Selzentry (Maraviroc)
- Study Demonstrates Aerosolized Prolastin Using Unique Nebulizer Results in High Levels of Drug Deposited in Peripheral Regions of Lungs
- Results of Pre-Clinical Investigations of Ceragenix's Developmental Antibiotic to Be Presented at International Scientific Meeting on Infectious Diseases
- Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
- RDEA806, A Potent, New HIV NNRTI With a High Genetic Barrier to Resistance and a Broad Spectrum of Activity, Introduced at 47th ICAAC
- Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic
- New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients With Complicated Skin Infections, Including MRSA
September 19, 2007
- Further Evidence for Lasting Immunological Efficacy of Diamyd Diabetes Vaccine
- Spectrum Pharmaceuticals Announces Presentation of SPI-1620 Data at the 10th International Conference on Endothelin
- Acceleron Pharma Presents Positive Phase 1 Results Demonstrating ACE-011 Increases Markers of Bone Formation
- New Phase 3 Study In Treatment-Naïve Adults With HIV Evaluates Efficacy And Safety Of Once-Daily Prezista/Ritonavir Vs. Kaletra As Part Of HIV Combination Therapy
- Zelos Therapeutics Presents Positive Data at ASBMR on Subcutaneous and Inhaled Delivery of Cyclic PTH (1-31) (Ostabolin-C(TM))
- News on HIV Gene Therapy Clinical Trial at ICAAC
- Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
- New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients With Complicated Skin Infections, Including MRSA
- Promising Early Data from Phase I/II Clinical Trial Using GenVec Vaccine Presented at Malaria Conference
- Results of Ceftobiprole Phase III Program for the Treatment of Complicated Skin Infections Presented Today at ICAAC
- CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
- Biodel Inc. Announces VIAject Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
- New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
- Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC
- Enzo Biochem Reports Animal Study Supports Finding of New Therapeutics for Treating Periodontal Bone Loss
- Rimonabant Effectively Reduces Visceral Fat in the Obese Patient as Confirmed by Abdominal Computer Tomography (ct) Scan
- Appropriate Glycemic Control Contributes to Reducing the Risk of Macrovascular Diseases in Patients with Diabetes
- New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
- Increased Bone Mineral Density Seen in Phase IIB Study with Odanacatib, Formerly MK-0822, An Investigational Cathepsin K Inhibitor
- Less Than One-Third of Women Aware of Landmark Hormone Therapy Study, Stanford Researcher Finds
- Preclinical Data on FermaVir's FV-100 Presented at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
- Iomai Patch-Based Vaccine Cut Rate of Travelers' Diarrhea by 75 Percent in Phase 2 Field Study
- Metabasis Therapeutics Announces the First Publication on MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, in the Proceedings of the National Academy of Sciences
- Teva Provides Update on Edratide for Systemic Lupus Erythematosus
- Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
- Actos (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
- Arpida Presents Preclinical and Clinical Data on Iclaprim at Icaac
- Eclipse Data on Effects of Otsuka's Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients' Hemodynamics and Urine Output Featured in Heart Failure Society of America's Late Breaking Trials
- Dynavax's Heplisav Hepatitis B Vaccine Maintains Full Immunogenicity at 50 Weeks in Phase 3 Trial
- New Data Show That GlaxoSmithKline's Rotarix(R) Could Be Given With Other Routine Infant Vaccines in the U.S.
- Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria
- Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
- Replidyne's Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile
September 20, 2007
- Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
- BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
- New Study Shows Once-Monthly Boniva is as Clinically Effective as Once-Weekly Fosamax at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
- Medivir: MIV-701 Preclinical Efficacy Data Presented
- Arpida Presents Preclinical and Clinical Data on AR-709 at ICAAC
- New Data Confirm Clear Benefit of Protelos (Strontium Ranelate) in the Treatment of Postmenopausal Osteoporosis
- Study Shows Vasopressin Receptor Antagonist Vaprisol (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
- Optimer Presents Positive Data on Two Lead Anti-Infective Drug Candidates
- Acceleron Pharma's ACE-011 Increases Bone Mineral Density and Bone Strength in Preclinical Studies in Non-Human Primates
- Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
- Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
- A key sign of vascular aging, arterial stiffness, reduced by leading blood pressure medication Diovan®
September 21, 2007
- New Data Shows That the Unique Levemir Weight Benefit Continues After Two Years of Treatment
- One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
- Arpida Presents Preclinical Data on AR-2474 at ICAAC
- NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
- Amgen Oncology Highlights Upcoming Data Presentations at the 2007 European Conference on Clinical Oncology
- The CYPHER Sirolimus-Eluting Coronary Stent Outperforms the Taxus Stent in Small Coronary Vessels According to New Clinical Data Analysis Published in the Journal of the American College of Cardiology
September 24, 2007
- Phase 3 Pivotal Trial of Tocosol Paclitaxel Does Not Meet Primary Endpoint
- Avastin Achieves Impressive Rate of Curative Surgery in Patients With Advanced Colorectal Cancer
- CytRx Provides Arimoclomol and Iroxanadine Clinical Trial Updates
- ChemGenex Announces Second Publication Demonstrating Activity of Ceflatonin in T315I-Positive Chronic Myeloid Leukemia (CML)
- Progen Announces PI-88 Phase 2 Lung Cancer Results
- Current Chemotherapy Regimens for Advanced Colorectal Cancer Prolong Survival
- Nventa announces publication of HspE7 data
- Summit plc Presents Zebrafish Data at International Safety Pharmacology Conference
September 25, 2007
- Orexigen Announces Positive Clinical Results of Its Proprietary Naltrexone Sustained Release Formulation for Use in Contrave
- New Research Published on Impact of Targeting on Biodistribution and Efficacy of siRNA Using Calando Pharmaceuticals' siRNA Delivery Technology
- Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European College of Clinical Oncology Annual (ECCO) Meeting
- Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
- Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes
- Aranesp DAHANCA 10 Study Results Presented at ECCO Annual Meeting
- New Biomarker Data Links KRAS Gene to Vectibix Clinical Response
- Positive Xeloda Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
- Data from Phase II Study of Gilead's Darusentan in Resistant Hypertension Published in Journal of Clinical Hypertension
- DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study
- GlaxoSmithKline Reports Positive New and Updated Data on Tyverb (lapatinib) at the 14th European Cancer Conference (ECCO)
- Alpharadin Treatment More Than Doubles Survival Rate in Prostate Cancer Patients
- BioAlliance Pharma: Results Presented at ECCO 2007 Further Confirm the Clinical Efficacy of BioAlliance Pharma's Antifungal, Particularly in Populations with High Risk of Candidiasis
- Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
- Data From Ongoing Hematological Trials With Darinaparsin Presented at European College of Clinical Oncology Annual Meeting
- Arpida’s Extensive Presence at ICAAC Well-Received
September 26, 2007
- CollaGenex Pharmaceuticals Announces Results of Phase 2 Dose-Finding Study of Incyclinide for the Treatment of Rosacea
- Promising Results in Treating Facial Bruising From Injectables
- Positive Glufosfamide Results From a Phase 2 Clinical Trial Presented at European Cancer Conference (ECCO)
- Alkermes and Indevus Announce Positive Results from Phase 2a Clinical Study of ALKS 27 for the Treatment of COPD
- Herceptin Eradicates Tumours and May Reduce The Need for Mastectomies in women with inflammatory HER2-Positive Breast Cancer
- Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting
- CollaGenex Pharmaceuticals Announces Results of Phase 2 Dose-Finding Study of Incyclinide for the Treatment of Rosacea
- Phase 2 Study Suggests That Extended Dosing of Aranesp is as Efficacious as Weekly Dosing
- New Analysis Suggests First Cycle Use of Neulasta Reduces Febrile Neutropenia Hospitalizations and Chemotherapy Dose Reductions in Breast Cancer Patients Compared to Current Practice
- New Phase III Data Demonstrate Oxycodone / Naloxone Combination Tablet Reduces Opioid-induced Bowel Dysfunction in Patients with Chronic Severe Pain
- Incyte Reports Positive Proof-of-Concept Results For INCB18424, Its Lead JAK Inhibitor, and INCB13739, its Lead 11beta-HSD1 Inhibitor
- Alkermes and Indevus Announce Positive Results from Phase 2a Clinical Study of ALKS 27 for the Treatment of COPD
- New Preliminary Phase II Data Show Anti-Tumor Activity of Single-Agent Sunitinib Malate in Advanced Gastric Cancer
- New Phase III Data Demonstrate Oxycodone / Naloxone Combination Tablet Reduces Opioid-Induced Bowel Dysfunction in Patients With Chronic Severe Pain
- Juvaris BioTherapeutics Announces Six Scientific Presentations at Infectious Diseases Society of America (IDSA) Meeting October 6, 2007
- New Study Shows Promise for Hydrogen Sulfide in Reducing Heart-Attack Damage, Ikaria Announces
- Diamyd Diabetes Vaccine Effective for at Least 21 Months
- ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth
- Alnylam and Collaborators Publish New Paper in the Journal Nature on the In Vivo Efficacy and Safety of RNAi Therapeutics
September 27, 2007
- Introgen Presents Biomarker Data Demonstrating Abnormal p53 Predicts ADVEXIN Efficacy in Head and Neck, Lung, Prostate and Li-Fraumeni Cancers
- Pharmacopeia Confirms Blockade of Angiotensin II Response with First-In-Class PS433540 (DARA)
- Positive Clinical Data On MediciNova's Product Candidate MN-029 Presented At the 14th European Cancer Conference (ECCO 14)
- Adventrx to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference
- Glufosfamide Results From Phase 3 Clinical Trial Presented at European Cancer Conference (ECCO)
- Nuvelo Announces Publication of NU206 Study Results in Proceedings of the National Academy of Sciences of the United States of America
- NKTR-102 (PEG-Irinotecan) Demonstrates Significant Anti-Tumor Activity and Improved Pharmacokinetic Profile in Preclinical Studies Presented at ECCO
- Palatin Technologies, Inc. Reports Positive Data from an At-home Study of Pre- and Postmenopausal Women with Female Sexual Arousal Disorder Treated with Bremelanotide
- ST-246 Completely Prevents Mortality in Symptomatic Orthopox Virus Infected Primates
- Study Shows Brostallicin in Combination with Cisplatin is Well-Tolerated and Produces Prolonged Disease Stabilization in Patients with Platinum-Resistant Cancers
- Nymox Announces BPH Drug Clinical Data Presentation Sept. 28 at American Urological Association Meeting
- New Scientific Data on Allergan's Botox (Botulinum Toxin Type A) Presented at the American Academy of Physical Medicine and Rehabilitation 68th Annual Assembly
- CDC Study Links Thimerosal in Vaccines to Motor/Phonic Tics and Deficits in Attention, Behavior Control, Verbal IQ
September 28, 2007
- Crucell Discovers Human Monoclonal Antibodies for the Prevention and Treatment of the Avian Flu Virus
- Diffusion Pharmaceuticals Announces Results of Phase I Human Trial of Lead Drug Candidate, Trans Sodium Crocetinate (TSC) and Completion of a $4.5 Million Private Placement
- Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination Reolysin and Radiation Clinical Trial
- Genes Linked to Suicidal Thinking During Antidepressant Treatment
